Articles

Nathalie Dubois-Stringfellow, Sangamo’s chief development officer discusses the company's diverse clinical programs, strategic collaborations, including a partnership with Pfizer, and the crucial role of patient safety.

Charting the Course of Gene Therapy: A Conversation with Sangamo Therapeutics

Former Executive Director, Association of Clinical Research Professionals

Jim Kremidas, former executive director, Association of Clinical Research Professionals, shares his experiences as a patient in clinical trials. 

Perspective and Hope From the ‘Other Side’

How retail pharmacies can harness their resources to improve clinical trial access.

Retail Pharmacies and Decentralized Clinical Trials: The Path Forward Despite Challenges

Staying the Course: Kroger Continues to Impact the Clinical Trials Landscape

In this Q&A, Craig Lipset offers additional insights following the announcement that CVS will be closing its clinical trial services business by the end of the year. 

CVS's Closure of Its Clinical Trial Unit and What it Means for The Future

In this Q&A, John Kastelein, MD, founder and chief scientific officer, NewAmsterdam Pharma, discusses the challenges and opportunities within the cardiovascular field, exploring the current landscape for lipid-lowering therapies and the unique potential advantages of CETP inhibitors. 

Breaking New Ground in Cardiovascular Health: Innovative Approaches in Clinical Trial Design

Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.

EU’s sweeping push for major pharma reforms to impact the daily practice of clinical trials community.

European Legislative Proposals Presage New Rules for Clinical Trials

Dissecting the EMA’s new annual report on milestones reached in clinical research and public health.

Transformations Past and Future for the European Medicines Agency

The journey of CVS Health’s clinical trials unit serves as a speculative case study, reminding us that venturing into new market areas, even for established companies, necessitates a careful evaluation of strategic fit, competition, infrastructure, financial constraints, and industry trends.



Why Did CVS Shutter its Clinical Trials Unit?

Key considerations for successful implementation in decentralized clinical trials.

Blogs